At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,163 enrolled
Drug / intervention
Nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Nivolumab, Ipilimumab, and 1 other intervention for Advanced or Metastatic Solid Tumors. Completed, enrolled 1,163 participants across 38 sites in 8 countries.
Detailed Summary
To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic Solid Tumors
CountriesCanada, Denmark, Finland, Germany, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartOct 2013
Primary CompletionFeb 2019
Study CompletionNov 2024
TodayJul 2026
First PostedAug 23, 2013
Enrollment StartOct 24, 2013
Primary CompletionFeb 5, 2019
Study CompletionNov 18, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.9 years ago
Interventions
Nivolumabbiological
Ipilimumabbiological
Cobimetinibdrug